Barclays
BBIO icon

Barclays’s BridgeBio Pharma BBIO Stock Holding History

Barclays’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,000
Closed -$928K – 4876
2024
Q1 		$928K Buy
+30,000
New +$1.02M ﹤0.01% 3171
2023
Q2 		– Sell
-2,100
Closed -$34.8K – 4565
2023
Q1 		$34.8K Buy
+2,100
New +$24.5K ﹤0.01% 4531

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's BBIO Position: Q1 2026 in Review

Barclays reduced its BridgeBio Pharma (BBIO) stake by 32% in Q1 2026, selling an estimated $14.4M and leaving 423,888 shares worth $31.5M. The position accounts for 0.01% of the portfolio, ranked #912.

Barclays first reported a position in BBIO in Q2 2019 and has held it in 28 quarters since. The position peaked at $47.6M in Q4 2025. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Barclays held 423,888 shares of BridgeBio Pharma worth $31.5M as of Q1 2026.
  • Barclays sold 198,687 BridgeBio Pharma shares in Q1 2026, an estimated $14.4M.
  • BridgeBio Pharma made up 0.01% of Barclays's portfolio in Q1 2026, its #912 holding.
  • Barclays first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 28 quarters since.
  • Barclays's BridgeBio Pharma position peaked at $47.6M in Q4 2025.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.